The FDA granted fast-track designation and priority review for Narcan nasal spray. Fast track is a process designed to facilitate development and expedite review of drugs intended to treat serious conditions and that demonstrate the potential to address an unmet medical need. The agency’s priority review program provides for an expedited review of drugs that offer a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. Narcan nasal spray is being approved in less than four months, significantly ahead of the product’s prescription drug user fee goal date of January 20, 2016.
Do not spray ATROVENT Nasal Spray % in your eyes. Should this occur, immediately flush your eye with cool tap water for several minutes. If you accidentally spray Atrovent Nasal Spray % in your eyes, you may experience a temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion, development or worsening of narrow-angle glaucoma, pupil dilation, or acute eye pain/discomfort, and increased sensitivity to light, which may last a few hours. Should acute eye pain or blurred vision occur, contact your doctor.
The most common side effects associated with fluticasone are headache , throat infection, nasal irritation, sneezing , cough , nausea , vomiting . Hypersensitivity reactions such as skin rash , itching , facial swelling, and anaphylaxis may occur. Some children may experience growth suppression when using fluticasone. A bloody nasal discharge ( nosebleed ) and septum perforation may occur. Fungal infection of the nose and throat, glaucoma , and cataracts are also associated with intranasal fluticasone.